Johnson & Johnson (JNJ) is an interesting player in the Healthcare space, with a focus on Drug Manufacturers – Major. The stock has been active on the tape, currently trading at $133.19, up from yesterday’s close by 0.23%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.
Does this stock stack up well when compared to its peers in the industry space? Let’s take a look. Johnson & Johnson (JNJ) currently trades with a market capitalization of $358.53 Billion.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For JNJ, the company currently has $12.6 Billion of cash on the books, which is offset by $7.21 Billion current liabilities. You can get a sense of how sustainable that is by a levered free cash flow of $17.61 Billion over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $1.8 on a per share basis this quarter. Perhaps, that suggests something about why 65.74% of the outstanding share supply is held by institutional investors.
It’s important to check the technicals to get a sense of how JNJ has been acting. Looking at the stock’s movement on the chart, Johnson & Johnson recorded a 52-week high of $137.08. It is now trading 3.89% off that level. The stock is trading $132.40 its 50-day moving average by -0.78999999999999%. The stock carved out a 52-week low down at $109.32.
In recent action, Johnson & Johnson (JNJ) has made a move of +0.76% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 17.45, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 0.57% with $2.68 Billion sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of JNJ.